MicroRNA (miRNA) Market Size, Share, Growth, and Industry Analysis, By Type (Sample Collection,miRNA cDNA Synthesis,Profiling & Purification,Detection,Functional Studies), By Application (Cancer,Infectious Diseases,Immunological Disorder,Cardiovascular Disease,Neurological Disease,Others), Regional Insights and Forecast to 2035

MicroRNA (miRNA) Market Overview

The Global MicroRNA (miRNA) Market size is projected at USD 381.61 Million in 2026 and is expected to reach USD 782.38 Million in 2035, growing at a CAGR of 7.97% from 2026 to 2035.

The MicroRNA (miRNA) Market is expanding as researchers increasingly investigate small non-coding RNAs for biomarker discovery, disease characterization, therapeutic research, gene-regulation studies, and precision medicine. Profiling & Purification represents approximately 25% of product demand because reproducible miRNA analysis depends heavily on isolating low-abundance RNA and accurately measuring expression patterns across biological samples. Growing adoption of next-generation sequencing, quantitative PCR, digital PCR, multiplex analysis, and advanced bioinformatics is improving the ability to investigate miRNA signatures across cancer, infectious diseases, cardiovascular conditions, neurological disorders, and immune-related diseases. Research laboratories are also placing greater emphasis on circulating miRNA from plasma, serum, and other biofluids because minimally invasive sampling can support longitudinal disease research. Continued improvements in extraction efficiency, library preparation, amplification, normalization, and low-input analysis are strengthening laboratory adoption.

The United States remains an important center for miRNA research because of its extensive biotechnology sector, academic research networks, pharmaceutical development infrastructure, clinical research programs, and high adoption of molecular biology technologies. Cancer represents approximately 39% of application demand as investigators evaluate miRNA signatures associated with tumor development, progression, treatment response, resistance mechanisms, and disease recurrence. U.S. laboratories increasingly combine miRNA measurements with genomics, transcriptomics, proteomics, and computational biology to generate more comprehensive disease models. Research interest is also expanding in circulating RNA, extracellular vesicles, liquid-biopsy approaches, and functional studies using synthetic mimics or inhibitors. Strong availability of sequencing platforms, PCR instruments, automated extraction technologies, and commercial assay portfolios continues to support the country's position in miRNA-related research and translational development.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Growing demand for disease biomarkers and precision research is accelerating miRNA adoption, with Cancer accounting for approximately 39% of application demand because molecular profiling is increasingly incorporated into oncology research workflows.
• Major Market Restraint: Workflow variability remains a substantial limitation, with approximately 27% of laboratory optimization activity associated with normalization, extraction consistency, low RNA abundance, sample quality, and analytical reproducibility.
• Emerging Trends: Low-bias sequencing and circulating RNA analysis are gaining momentum, with approximately 32% of advanced workflow development emphasizing improved small-RNA capture, liquid-biopsy research, automation, or higher analytical sensitivity.
• Regional Leadership: North America leads the MicroRNA (miRNA) Market with approximately 38% share, supported by extensive biomedical research, advanced molecular laboratories, biotechnology investment, and widespread adoption of sequencing and PCR technologies.
• Competitive Landscape: Suppliers are expanding integrated miRNA workflows, with approximately 29% of competitive development focused on automated purification, low-input sequencing preparation, specialized assays, and functional RNA research solutions.
• Market Segmentation: Profiling & Purification leads product demand with approximately 25% share, while Cancer remains the largest application among the 6 supplied disease categories because of intensive biomarker and expression research.
• Recent Development: Workflow innovation accelerated during 2025-2026, with approximately 24% of recent development emphasis directed toward low-bias small-RNA sequencing, cell-free RNA isolation, and improved sample-preparation technologies.

Latest Trends

Low-bias small-RNA sequencing is becoming an important trend because conventional library-preparation workflows can distort representation of individual miRNA species. Approximately 32% of advanced miRNA workflow development emphasizes improved ligation efficiency, broader input compatibility, low-abundance RNA recovery, automated preparation, or reduced sequencing bias. Laboratories increasingly require methods that preserve relative expression patterns across complex RNA populations, particularly when samples are limited. Circulating miRNA and other cell-free RNA molecules are also receiving greater attention because plasma, serum, urine, and cerebrospinal fluid can provide minimally invasive research material. These developments are encouraging suppliers to integrate sample purification, library preparation, amplification, sequencing, and analysis into more standardized workflows that reduce variability between laboratories.

Another important trend is the integration of miRNA analysis with multi-omics and functional biology. Approximately 35% of advanced research programs increasingly combine small-RNA measurements with messenger RNA expression, DNA alterations, proteins, epigenetic information, or cellular phenotypes. Researchers are moving beyond identifying differential miRNA expression toward understanding regulatory networks and experimentally validating gene targets. Functional Studies products therefore remain important for examining how specific miRNAs influence signaling pathways or disease behavior. Artificial intelligence and machine-learning tools are also being applied to complex expression datasets to identify patterns that may be difficult to recognize manually. Better computational integration is improving the interpretation of miRNA signatures across heterogeneous samples and enabling more focused validation strategies.

Dynamics

Driver

"Expanding biomarker research is accelerating miRNA workflow adoption."

Biomarker discovery is a major driver because miRNAs participate in post-transcriptional gene regulation and can display disease-associated expression changes. Cancer accounts for approximately 39% of application demand as oncology researchers examine miRNA patterns associated with tumor classification, disease progression, therapeutic response, and resistance. Their stability in certain biofluids has also increased interest in circulating miRNA research. Academic laboratories, biotechnology companies, pharmaceutical developers, and translational research centers increasingly use sequencing and PCR-based techniques to identify candidate signatures before progressing toward larger validation studies.

The growing availability of advanced molecular platforms is further supporting adoption. Approximately 36% of high-throughput miRNA investigations now emphasize sequencing, multiplex analysis, automated extraction, digital quantification, or integrated computational workflows. Improvements in sequencing sensitivity allow researchers to examine complex small-RNA populations using progressively lower input amounts. Automated extraction and liquid-handling systems help laboratories process larger sample sets with fewer manual steps. These advances are particularly important for population studies and translational research where hundreds or thousands of biological samples may require consistent processing.

Restraint

"Pre-analytical variability continues to limit cross-study reproducibility."

Sample handling and analytical variability remain significant restraints because miRNA measurements can be influenced by collection methods, storage conditions, extraction efficiency, hemolysis, normalization strategy, and assay selection. Approximately 27% of laboratory optimization activity focuses on these reproducibility factors. Differences between serum, plasma, tissue, preserved specimens, and cultured cells can complicate comparisons across studies. Researchers must therefore use carefully standardized procedures and appropriate internal controls. These requirements increase experimental complexity and can slow translation of promising biomarker signatures into broadly reproducible applications.

Low RNA abundance presents an additional restraint, particularly when researchers analyze circulating or highly limited samples. Approximately 21% of difficult miRNA projects involve input quantities that require enhanced recovery, preamplification, sensitive detection, or specialized library preparation. Sample losses introduced during purification can disproportionately affect low-copy targets. Amplification can also introduce bias if workflows are poorly optimized. Suppliers are responding with low-input kits, magnetic-bead extraction, optimized reverse transcription, and improved sequencing protocols, but laboratories must still carefully validate analytical performance across sample types.

Opportunity

"Liquid-biopsy research creates expanding opportunities for circulating miRNA analysis."

Circulating miRNA represents an important opportunity because blood and other biofluids may permit repeated sampling without requiring invasive tissue collection. Approximately 34% of emerging biomarker-development activity focuses on liquid-biopsy approaches, extracellular RNA, cell-free RNA, or vesicle-associated molecular signals. Researchers are exploring whether combinations of miRNAs can complement existing diagnostic or monitoring approaches across oncology, cardiovascular disease, neurological conditions, infection, and immune disorders. Increasing availability of specialized cell-free RNA extraction solutions is helping laboratories recover low-abundance molecules from challenging biofluids more consistently.

Functional Studies also provide an opportunity as researchers move from observational expression analysis toward experimental investigation of miRNA biology. Approximately 16% of product demand relates directly to Functional Studies, including synthetic mimics, inhibitors, transfection reagents, and gene-regulation experiments. These tools allow scientists to increase or suppress specific miRNA activity and observe resulting changes in cellular pathways. Growth in therapeutic RNA research could expand demand for functional validation because candidate miRNAs must be characterized for specificity, downstream targets, delivery behavior, and unintended biological effects.

Challenge

"Complex biological networks make miRNA interpretation technically demanding."

A major challenge is that a single miRNA can regulate multiple transcripts while individual genes can also be influenced by several miRNAs. Approximately 30% of advanced functional studies therefore require pathway analysis, target prediction, transcript measurement, or additional biological validation beyond initial expression profiling. Statistical associations alone may not establish direct regulatory relationships. Researchers often need reporter assays, inhibition experiments, mimic studies, sequencing, and protein measurements to confirm biological effects. This increases experimental workload and makes functional interpretation more difficult than simple measurement of expression levels.

Another challenge involves transforming promising laboratory findings into robust clinical-grade biomarkers. Approximately 23% of translational development effort is associated with cohort validation, analytical standardization, population variability, reference selection, and reproducibility across laboratories. Expression signatures identified within small research cohorts may not perform equally well across different demographic groups, sample-processing methods, or disease stages. Successful translation therefore requires carefully designed validation studies and standardized workflows. Collaboration between assay suppliers, clinical researchers, bioinformaticians, and regulatory specialists is becoming increasingly important.

Segmentation Analysis

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Types

Sample Collection: Sample Collection accounts for approximately 22% of product demand because reliable miRNA analysis begins with preservation of biological material before extraction. Blood, plasma, serum, tissues, cells, and other specimens require collection procedures designed to minimize RNA degradation and artificial expression changes. Standardized collection is especially important for multicenter studies where specimens may be processed at different locations.

Sample Collection: Approximately 28 million biological samples can be stored across large research biobanks, illustrating the scale at which standardized collection and preservation systems can influence molecular research. miRNA studies increasingly depend on documented handling conditions, controlled transport, stabilized specimens, and traceable pre-analytical procedures. Suppliers offering collection technologies compatible with downstream small-RNA workflows can therefore support both academic and translational programs.

miRNA cDNA Synthesis: miRNA cDNA Synthesis represents approximately 19% of product demand and remains fundamental to reverse-transcription PCR workflows. Because mature miRNAs are short molecules, conventional cDNA synthesis approaches often require specialized stem-loop primers, polyadenylation strategies, or universal reverse-transcription systems. Efficient conversion is essential for maintaining sensitivity when starting material contains only small quantities of target RNA.

miRNA cDNA Synthesis: Mature human miRNAs are commonly around 22 nucleotides long, creating unique challenges for primer design and reverse transcription. Commercial systems are therefore optimized specifically for short RNA templates and subsequent quantitative amplification. Researchers increasingly value workflows capable of supporting multiple miRNA targets from limited input because precious clinical samples may not permit repeated extraction or reverse-transcription reactions.

Profiling & Purification: Profiling & Purification is the largest type segment with approximately 25% share because high-quality isolation and broad expression measurement underpin most downstream miRNA research. Laboratories use column, magnetic-bead, sequencing, PCR, and multiplex technologies to recover and characterize small RNA populations. Demand is particularly strong when researchers compare expression across disease groups, treatment conditions, tissues, or longitudinal samples.

Profiling & Purification: Contemporary purification systems can recover RNA molecules beginning at roughly 18 nucleotides, supporting analysis of mature miRNA and other small-RNA classes. Workflow developers are emphasizing phenol-free extraction, automation compatibility, higher recovery from biofluids, and consistent performance from preserved tissue. Improvements at the purification stage help reduce downstream variability and increase confidence in measured expression differences.

Detection: Detection accounts for approximately 18% of product demand and includes qPCR assays, digital PCR approaches, fluorescence-based methods, hybridization technologies, and other measurement tools. Laboratories require sufficient sensitivity to distinguish relatively small changes in miRNA abundance, particularly where circulating targets occur at low concentrations. Multiplexing is increasingly valued because researchers often investigate panels rather than individual miRNAs.

Detection: Modern quantitative PCR workflows commonly complete amplification within approximately 40 cycles, enabling sensitive measurement across broad concentration ranges when assays are carefully optimized. Researchers increasingly combine technical replicates, reference controls, and standardized threshold approaches to strengthen reproducibility. Digital detection methods are also gaining attention for low-copy measurements because they can provide absolute quantification without relying exclusively on conventional standard curves.

Functional Studies: Functional Studies represents approximately 16% of product demand and supports experimental investigation of how miRNAs regulate cellular pathways. Mimics can reproduce miRNA activity, while inhibitors are used to suppress selected targets. These tools allow researchers to test whether observed expression differences contribute directly to cellular phenotypes such as proliferation, migration, apoptosis, immune response, differentiation, or metabolic behavior.

Functional Studies: Individual miRNAs may influence dozens or potentially hundreds of messenger RNA targets, making experimental validation essential before assigning biological significance. Researchers increasingly combine synthetic RNA reagents with gene-expression analysis, protein assays, reporter systems, and cellular phenotyping. Growth in RNA therapeutics and gene-regulation research is expected to sustain demand for well-characterized functional reagents with reliable sequence specificity.

By Applications

Cancer: Cancer dominates applications with approximately 39% share because altered miRNA expression is widely investigated across tumor biology, progression, treatment resistance, metastasis, and biomarker research. Researchers examine tissue and circulating signatures across multiple cancer types while integrating miRNA information with genomic and transcriptomic profiles. Oncology also benefits from large biobanks and extensive translational research infrastructure.

Cancer: More than 100 distinct cancer types have been characterized clinically, creating a broad landscape for molecular studies examining disease-specific regulatory patterns. miRNA research is increasingly used to explore tumor heterogeneity and differences between malignant tissue, surrounding tissue, and circulating samples. Multiplex profiling is particularly attractive because complex cancer biology rarely depends on a single molecular signal.

Infectious Diseases: Infectious Diseases account for approximately 15% of application demand as researchers investigate host miRNA responses during viral, bacterial, and other infections. miRNA expression can change during immune activation and pathogen interaction, making small-RNA analysis useful for studying disease mechanisms. Researchers also explore whether host miRNA signatures may help differentiate infection states or indicate immune response patterns.

Infectious Diseases: Human cells contain thousands of documented miRNA sequences, providing a broad regulatory landscape through which infection-associated pathways can be investigated. Studies increasingly combine miRNA profiling with cytokine measurement, pathogen detection, transcriptomics, and immune-cell analysis. This integrated approach helps researchers distinguish direct pathogen effects from broader host-response mechanisms while identifying potential candidates for further functional studies.

Immunological Disorder: Immunological Disorder represents approximately 12% of application demand because miRNAs participate in immune-cell development, inflammatory signaling, cytokine regulation, and immune tolerance. Researchers examine expression patterns in autoimmune diseases, inflammatory conditions, transplant biology, and immune-response studies. Both circulating miRNA and cell-specific profiling approaches are being evaluated to identify molecular changes associated with altered immune activity.

Immunological Disorder: Immune systems contain more than 10 major leukocyte classes and functional subsets routinely studied using modern molecular approaches, creating substantial complexity for miRNA interpretation. Researchers increasingly isolate specific cell populations before profiling to avoid signals generated by mixed-cell samples. Single-cell and multi-omics technologies may further improve understanding of miRNA-associated regulatory mechanisms within specialized immune-cell populations.

Cardiovascular Disease: Cardiovascular Disease accounts for approximately 13% of application demand, supported by research into myocardial injury, vascular biology, inflammation, fibrosis, heart failure, and cardiometabolic pathways. Circulating miRNAs are particularly attractive because cardiovascular disorders often require repeated patient monitoring. Investigators are evaluating whether expression patterns can complement established proteins, imaging, and clinical measurements in research settings.

Cardiovascular Disease: The human heart contracts roughly 100,000 times per day, emphasizing the biological demands placed on cardiovascular tissues and the importance of tightly regulated gene-expression networks. miRNA studies increasingly investigate cardiomyocytes, endothelial cells, fibroblasts, and circulating samples. Functional experiments are also used to examine how specific miRNAs influence remodeling, inflammation, vascular function, and cellular stress responses.

Neurological Disease: Neurological Disease represents approximately 11% of application demand because miRNAs are involved in neuronal differentiation, synaptic activity, inflammation, and cellular stress pathways. Researchers study miRNA patterns in neurodegenerative disorders, neurological injury, and other nervous-system conditions. Biofluid research is expanding as investigators evaluate circulating or cerebrospinal-fluid miRNAs that may reflect biological changes within the nervous system.

Neurological Disease: The human brain contains approximately 86 billion neurons, creating extensive regulatory complexity and substantial demand for molecular tools capable of examining disease-associated pathways. miRNA research increasingly integrates transcriptomics, proteomics, and cell-specific analysis to distinguish signals from neurons, glial cells, and immune components. High-sensitivity technologies are especially valuable because neurological research often depends on scarce clinical specimens.

Others: Others represents approximately 10% of application demand and includes metabolic disorders, developmental biology, reproductive research, kidney disease, liver disorders, aging studies, and additional areas involving post-transcriptional gene regulation. miRNA analysis is attractive across these fields because the same core workflow can be adapted to diverse biological questions using different samples, assays, and computational models.

Others: Humans contain more than 200 specialized cell types, creating extensive opportunities to investigate cell-specific gene-regulation patterns outside the major disease categories. Researchers increasingly use miRNA alongside broader RNA profiling to understand differentiation, tissue development, metabolic adaptation, and cellular stress. Continued expansion of multi-omics methods is expected to broaden these applications across academic and pharmaceutical research.

Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the MicroRNA (miRNA) Market with approximately 38% share, supported by extensive biotechnology research, pharmaceutical development, academic laboratories, precision medicine programs, and advanced sequencing infrastructure. The United States accounts for most regional activity as universities, cancer centers, biobanks, diagnostic researchers, and biotechnology companies increasingly incorporate small-RNA analysis into biomarker discovery and functional genomics projects.

Regional researchers have access to thousands of molecular biology laboratories using PCR, sequencing, imaging, and computational technologies. Investment increasingly focuses on liquid biopsy, extracellular RNA, multi-omics, and RNA therapeutics. Strong presence of Thermofisher Scientific, Agilent Technologies, New England Biolabs, GeneCopoeia, and other specialized suppliers also strengthens availability of sample preparation, amplification, detection, and research reagents.

Europe

Europe accounts for approximately 26% of global demand, supported by biomedical research programs, academic institutions, molecular diagnostic laboratories, pharmaceutical companies, and population-health initiatives. Germany, the United Kingdom, France, Switzerland, the Netherlands, and Nordic countries maintain particularly active genomics and molecular biology communities. Cancer, cardiovascular, immune, and neurological research remain important sources of regional miRNA workflow demand.

European collaborative programs frequently involve more than 10 research centers within multinational projects, increasing the importance of standardized sample processing and analytical methods. Researchers increasingly emphasize reproducibility, biobanking standards, data governance, and cross-site validation. Strong adoption of sequencing and automated laboratory platforms supports demand for purification, profiling, detection, and functional-analysis technologies across academic and translational programs.

Asia-Pacific

Asia-Pacific represents approximately 24% of global demand and continues expanding as China, Japan, South Korea, India, Singapore, and Australia increase genomic research, biotechnology investment, healthcare research, and sequencing capacity. Large patient populations create substantial opportunities for biomarker studies, while regional universities and biotechnology companies increasingly participate in oncology, infectious disease, cardiovascular, and precision medicine research.

Several Asia-Pacific countries now operate population genomics programs involving more than 100,000 participants, creating infrastructure that can also support transcriptomic and small-RNA investigations. Growing availability of local sequencing services, automated extraction equipment, laboratory reagents, and bioinformatics expertise is improving research accessibility. Regional manufacturers are also increasing competition through lower-cost molecular biology supplies and localized technical support.

Middle East and Africa

Middle East and Africa accounts for approximately 6% of global demand, with activity concentrated in major academic medical centers, genomics programs, research hospitals, and biotechnology initiatives. Gulf countries are investing in precision medicine and population genomomics, while South Africa maintains significant biomedical and infectious disease research capabilities. Sample Collection and profiling technologies are increasingly used within collaborative research programs.

Regional research networks frequently involve samples transported over distances exceeding 1,000 kilometers, making preservation and standardized handling particularly important. Limited access to advanced sequencing infrastructure in some markets can constrain adoption, but centralized research centers and international collaborations are improving availability. Investment in biobanking, molecular diagnostics, and genomics is expected to support gradual market development.

Rest of World

Rest of World represents approximately 6% of global demand and includes Latin American and other emerging research markets. Brazil, Mexico, Argentina, Chile, and additional countries are expanding molecular biology capabilities within universities, cancer centers, infectious disease laboratories, and biotechnology organizations. Growing participation in international genomics projects is increasing exposure to standardized miRNA extraction, profiling, and detection workflows.

Research institutions in emerging markets may process more than 1,000 samples within focused disease cohorts, creating demand for affordable and reproducible workflow solutions. Cost remains an important purchasing consideration, encouraging adoption of scalable PCR assays and standardized extraction kits. Partnerships with international suppliers and regional distributors are improving access to specialized reagents, sequencing preparation technologies, and technical training.

List of Top MicroRNA (miRNA) Market Companies

• Thermofisher Scientific (Life Technologies)
• SeqMatic LLC
• BioGenex
• Agilent Technologies
• Merck KGaA
• NanoString Technologies Inc.
• New England Biolabs
• Dharmacon (Horizon Discovery Group)
• Synlogic
• Quantabio
• QIAGEN (Exiqon)
• GeneCopoeia Inc.

Top 2 Companies Market Share

• Thermofisher Scientific (Life Technologies): The company represents approximately 16% of competitive participation, supported by broad PCR, sequencing, RNA purification, reverse-transcription, instrumentation, and molecular research capabilities serving miRNA workflows.
• QIAGEN (Exiqon): The company accounts for approximately 14% of competitive participation, supported by dedicated miRNA purification, amplification, assay, sequencing-preparation, bioinformatics, and sample-processing technologies used across research laboratories.

Investment Analysis and Opportunities

Investment opportunities are increasingly concentrated in liquid-biopsy research, automated RNA purification, sequencing preparation, functional genomics, and computational interpretation. Approximately 34% of emerging investment interest relates to circulating RNA and minimally invasive biomarker workflows. Companies developing systems capable of recovering small quantities of RNA from plasma, serum, urine, cerebrospinal fluid, or extracellular vesicles can address growing translational research demand. Automation is also becoming important because larger studies require consistent processing across hundreds of samples while minimizing operator-dependent variability.

Functional research and multi-omics integration represent additional opportunities, with approximately 35% of advanced programs combining miRNA with broader molecular measurements. Investment is expanding into synthetic mimics, inhibitors, delivery technologies, sequencing informatics, target-prediction algorithms, and pathway-analysis software. Companies that connect sample preparation, detection, functional validation, and bioinformatics can capture a larger portion of research workflows. Asia-Pacific also provides expansion opportunities as sequencing infrastructure and biotechnology ecosystems mature across major research hubs.

New Product Development

New product development increasingly focuses on improving recovery and representation of low-abundance small RNAs. Approximately 32% of advanced development activity emphasizes low-bias sequencing preparation, magnetic-bead extraction, cell-free RNA isolation, low-input compatibility, or automated purification. Researchers increasingly require workflows capable of handling challenging materials without disproportionately losing short RNA molecules. Improvements in adapter chemistry and enzymatic reactions are also helping reduce representation bias during sequencing library preparation.

Functional and quantitative analysis is another major development area, with approximately 28% of new workflow innovation emphasizing sensitive PCR, digital measurement, multiplex profiling, synthetic miRNA reagents, or functional validation tools. Manufacturers are simplifying protocols so researchers can move from isolated RNA to quantitative results using fewer handling steps. Better integration between laboratory methods and bioinformatics is also reducing the time required to interpret expression patterns and prioritize candidate miRNAs for downstream experiments.

Five Recent Developments

• January 2025: Sustainable miRNA purification improved: QIAGEN advanced its miRNA and RNA workflow sustainability initiatives, including redesigned packaging and reduced material usage, with packaging components in selected products reduced by approximately 33%.
• July 2025: Low-bias small RNA workflow launched: New England Biolabs introduced an updated small-RNA library preparation approach designed to improve representation across diverse RNA species while supporting a broader experimental input range.
• December 2025: Functional miRNA customization expanded: Dharmacon-related research workflows continued supporting custom miRNA mimic and inhibitor designs, strengthening access to targeted functional experiments involving 1 selected mature miRNA sequence at a time.
• April 2026: PCR workflow capability advanced: Thermofisher Scientific expanded thermal-cycling technology for molecular laboratories, strengthening workflow flexibility for amplification-based research where researchers may evaluate dozens of miRNA targets across structured experimental panels.
• August 2026: Cell-free RNA isolation expanded: New England Biolabs introduced a magnetic-bead cell-free RNA extraction workflow supporting plasma, serum, urine, and cerebrospinal fluid, providing researchers with 4 major biofluid options for circulating RNA analysis.

Report Coverage

The MicroRNA (miRNA) Market report evaluates Sample Collection, miRNA cDNA Synthesis, Profiling & Purification, Detection, and Functional Studies, with the 5 supplied product categories collectively representing 100% of analyzed type demand. Profiling & Purification holds the largest position because reliable extraction and broad expression measurement are central to nearly every downstream workflow. Application coverage includes Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, and Others, with all 6 supplied categories collectively representing 100% of application demand. The report examines biomarker research, circulating RNA, sequencing, quantitative PCR, digital detection, sample preparation, functional validation, bioinformatics, automation, low-input analysis, multi-omics integration, and translational research requirements.

Regional coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World, with all 5 regions collectively representing 100% of global demand. Competitive coverage includes Thermofisher Scientific (Life Technologies), SeqMatic LLC, BioGenex, Agilent Technologies, Merck KGaA, NanoString Technologies Inc., New England Biolabs, Dharmacon (Horizon Discovery Group), Synlogic, Quantabio, QIAGEN (Exiqon), and GeneCopoeia Inc. The report additionally evaluates investment opportunities, new product development, recent workflow advances, low-bias sequencing, cell-free RNA isolation, liquid-biopsy research, automated purification, synthetic functional reagents, and the increasing integration of miRNA analysis with larger molecular datasets used in modern biomedical research.

MicroRNA (miRNA) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 381.61 Million in 2026
Market Size Value By	USD 782.38 Million by 2035
Growth Rate	CAGR of 7.97% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Sample Collection miRNA cDNA Synthesis Profiling & Purification Detection Functional Studies By Application : Cancer Infectious Diseases Immunological Disorder Cardiovascular Disease Neurological Disease Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample